Comparable stake leader
Ayrton Capital LLC
SEC ownership of PharmaCyte Biotech, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001157075.
Disclosed value leader
Ayrton Capital LLC
Comparable rows
35/50
Latest evidence
31 Mar 2026
- Public ticker
- PMCB on Nasdaq
- Parsed ownership sources
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- Ayrton Capital LLC
- Latest 13D/G holder
- Ayrton Capital LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001157075
- Issuer location
- Las Vegas, NV
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PharmaCyte Biotech, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ayrton Capital LLC
Disclosed value leader
Ayrton Capital LLC
Comparable rows
35/50
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 9.9%
15 rows are not safely comparable across share classes.
13D/G row: Ayrton Capital LLC
Showing 1-8 of 50 holder rows.
Quick read
Ayrton Capital LLC leads the comparable SEC ownership view at 9.9%.
35 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ayrton Capital LLC's linked filing trail.
Comparable ownership
Top 5
Ayrton Capital LLC
9.9%
INTRACOASTAL CAPITAL, LLC
5%
Joshua Silverman
4.4%
CITADEL ADVISORS LLC
3.4%
GEODE CAPITAL MANAGEMENT, LLC
1.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ayrton Capital LLC |
13D/G
|
9.9%
|
$967,625
774,100 shares
|
$0 | 31 Dec 2024 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
$484,351
532,254 shares
|
$0 | 31 Dec 2025 |
| Joshua Silverman |
3/4/5
CEO and President, Director
|
4.4%
|
$397,694
466,250 shares
|
+$80,476 | 05 Jan 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
3.4%
|
$239,243
359,547 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.8%
|
$130,200
195,660 shares
|
— | 31 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.53%
|
$37,595
56,500 shares
|
— | 31 Mar 2026 |
| XTX Topco Ltd |
13F
Company
|
0.49%
|
$34,842
52,362 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.48%
|
$34,226
51,467 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$128,708.
Buys
$128,708
Insiders: 2
Sells
$0
Insiders: 0
Net
+$128,708
Shares: +160,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 160,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 160,000 | 0 | $128,708 | $0 | +$128,708 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to PharmaCyte Biotech, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Joshua Silverman
Net 12M change
+$128,708
Latest report
31 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Joshua Silverman | CEO and President, Director | $397,694 | +$80,476 | +25% | Mixed | 05 Jan 2026 |
| Jonathan Schechter | Director | $162,393 | +$48,232 | +42% | Filing P/S | 31 Mar 2026 |
| Robert Weinstein | Director | $42,075 | Mixed | 31 Mar 2026 | ||
| Michael M. Abecassis | Director | $23,417 | Mixed | 31 Mar 2026 | ||
| Wayne Remell Walker | Director | $21,037 | Mixed | 31 Mar 2026 | ||
| Carlos A. Trujillo | Chief Financial Officer, Director | Mixed | 20 Nov 2023 | |||
| Matthias Loehr | Director | Mixed | 31 Mar 2022 | |||
| Daniel Stuart Farb | Director | Mixed | 28 Dec 2022 | |||
| Daniel Allen | Director | Mixed | 28 Dec 2022 | |||
| Gerald W. Crabtree | Chief Science Officer, Director | Mixed | 10 Aug 2021 | |||
| Thomas C. K. Yuen | Director | Mixed | 10 Aug 2021 | |||
| Jack E. Stover | Director | Mixed | 15 Aug 2022 | |||
| Thomas Liquard | Director | Mixed | 10 Aug 2021 | |||
| Kenneth L. Waggoner | Chairman, CEO, Pres and GC, Director | Mixed | 10 Aug 2021 | |||
| Raymond Cf Tong | Director | Mixed | 10 Aug 2021 |
Recent insider transactions for PharmaCyte Biotech, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert Weinstein | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Wayne R. Walker | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Jonathan Schechter | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Michael M. Abecassis | PMCB | Stock Option (Right to Buy) | Award | 119,170 | 119,170 | 31 Mar 2026 | Direct | |||
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 10.6% | $33,316 | $0.8329 | 40,000 | 416,250 | 07 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 11.6% | $16,872 | $0.8436 | 20,000 | 192,500 | 07 Jan 2026 | Direct |
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 8.66% | $23,667 | $0.7889 | 30,000 | 376,250 | 06 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 13.1% | $15,808 | $0.7904 | 20,000 | 172,500 | 06 Jan 2026 | Direct |
| Joshua N. Silverman | PMCB | Common Stock | Purchase | 9.49% | $23,493 | $0.7831 | 30,000 | 346,250 | 05 Jan 2026 | Direct |
| Jonathan Schechter | PMCB | Common Stock | Purchase | 15.1% | $15,552 | $0.7776 | 20,000 | 152,500 | 05 Jan 2026 | Direct |
| Robert Weinstein | PMCB | Common Stock | Tax liability | -45% | -33,750 | 41,250 | 12 Dec 2025 | Direct | ||
| Robert Weinstein | PMCB | Common Stock | Award | 75,000 | 75,000 | 12 Dec 2025 | Direct | |||
| Wayne R. Walker | PMCB | Common Stock | Tax liability | -45% | -16,875 | 20,625 | 12 Dec 2025 | Direct | ||
| Wayne R. Walker | PMCB | Common Stock | Award | 37,500 | 37,500 | 12 Dec 2025 | Direct | |||
| Joshua N. Silverman | PMCB | Common Stock | Tax liability | -45% | -258,750 | 316,250 | 12 Dec 2025 | Direct | ||
| Joshua N. Silverman | PMCB | Common Stock | Award | 575,000 | 575,000 | 12 Dec 2025 | Direct | |||
| Jonathan Schechter | PMCB | Common Stock | Tax liability | -33.8% | -67,500 | 132,500 | 12 Dec 2025 | Direct | ||
| Jonathan Schechter | PMCB | Common Stock | Award | 300% | 150,000 | 200,000 | 12 Dec 2025 | Direct | ||
| Michael M. Abecassis | PMCB | Common Stock | Tax liability | -43.1% | -16,875 | 22,292 | 12 Dec 2025 | Direct | ||
| Michael M. Abecassis | PMCB | Common Stock | Award | 2249.6% | 37,500 | 39,167 | 12 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.